evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Fluoxetine vs placebo

Any adverse event (N) · overweight or obese adults

Summary of findings: fluoxetine showed no clear difference in any adverse event (N) compared with placebo (low certainty).

1 finding from 1 review

Fluoxetine vs placebo

Morbidity: depression (N) · overweight or obese adults

It is very uncertain whether summary of findings: fluoxetine changes morbidity: depression (N) compared with placebo (very low certainty).

1 finding from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + GLP1‐A
2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + DPP4‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).

3 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + thiazolidinedione

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + thiazolidinedione compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + nateglinide
4 findings from 1 review
Show 1 more finding

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + SGLT2‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + SGLT2‐I compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review

Intraoperative neuromonitoring vs visual nerve identification only during thyroidectomy

Permanent RILN palsy (nerves) Definition: injury detected clinically, by laryngoscopy or both, in which the motility of the vocal cords did not recover within 6 months after surgery

It is very uncertain whether intraoperative neuromonitoring changes permanent RILN palsy (nerves) Definition: injury detected… compared with visual nerve identification only during thyroidectomy (very low certainty).

1 finding from 1 review

Intraoperative neuromonitoring vs visual nerve identification only during thyroidectomy

Transient RILN palsy (nerves) Definition: injury detected clinically, by laryngoscopy or both, in which the motility of the vocal cords recovered within 6 months after surgery

It is very uncertain whether intraoperative neuromonitoring changes transient RILN palsy (nerves) Definition: injury detected… compared with visual nerve identification only during thyroidectomy (very low certainty).

1 finding from 1 review

Intraoperative neuromonitoring vs visual nerve identification only during thyroidectomy

Adverse events other than RILN palsy (participants) Definition: transient hypoparathyroidism

It is very uncertain whether intraoperative neuromonitoring changes adverse events other than RILN palsy (participants) Definition:… compared with visual nerve identification only during thyroidectomy (very low certainty).

1 finding from 1 review